The Inflation Reduction Act (IRA) is helping people with Medicare afford their medications, including the 2.1 million Asian, 5.8 million Black, and 5.3 million Latino Part D enrollees. These fact sheets review existing research to present the projected impacts of key IRA Medicare drug-related provisions for these populations.
Healthcare Reform
Reports
Displaying 11 - 20 of 118. 10 per page. Page 2.
Advanced SearchFact Sheet, Report
Inflation Reduction Act Research Series: Understanding Development and Trends in Utilization and Spending for Drugs Selected Under the Medicare Drug Price Negotiation Program
The Inflation Reduction Act (IRA) authorizes the Secretary of the Department of Health and Human Services (HHS) to negotiate prices directly with participating manufacturers for selected drugs that are high expenditure, single source drugs without generic or biosimilar competition.
Report
Inflation Reduction Act Research Series: Medicare Part D Enrollee Out-of-Pocket Spending: Recent Trends and Projected Impacts of the Inflation Reduction Act
The Inflation Reduction Act (IRA) will make key changes to improve drug affordability for people who have Medicare.
ASPE Issue Brief
Medicare Part B Drugs: Trends in Spending and Utilization, 2008-2021
The U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Planning and Evaluation (ASPE) released new research on spending and utilization trends of Medicare Part B drugs, drugs administered in physicians' office or hospital outpatient departments rather than being purchased at the pharmacy counter or by mail order.
ASPE Issue Brief
Inflation Reduction Act Research Series: Medicare Part D Enrollee Savings from Elimination of Vaccine Cost-Sharing
Effective January 1, 2023, the Inflation Reduction Act (IRA) eliminated enrollee cost-sharing for recommended vaccines covered under Medicare Part D. In 2021, 3.4 million people received vaccines under Part D, and annual out-of-pocket costs were $234 million.
ASPE Issue Brief
Trends in Prescription Drug Spending, 2016-2021
High prescription drug costs are a leading concern among Americans. Americans pay higher prices for prescription drugs than any other country in the world, with prescription drug prices in the U.S. more than 2.5 times as high as those in other similar high-income nations.
ASPE Issue Brief
State Use of Value-Based Payment in Nursing Facilities Issue Brief
Payers across the health care spectrum have begun transitioning from paying for quantity toward paying for quality. These value-based payment (VBP) programs vary in scope and focus, but generally share the goals of improving cost-savings and linking payments to value rather than volume.
ASPE Issue Brief
Health Insurance Coverage and Access to Care Among Black Americans: Recent Trends and Key Challenges
This issue brief analyzes changes in health insurance coverage and examines trends in access to care among Black Americans using data from 2011-2020. This Issue Brief is part of a series of ASPE reports examining the change in coverage rates and access to care after implementation of the Affordable Care Act (ACA) among different racial and ethnic populations.
ASPE Issue Brief
Health Insurance Deductibles Among HealthCare.gov Enrollees, 2017-2021
The Affordable Care Act provides premium subsidies for Marketplace eligible individuals to improve health insurance affordability, as well as cost-sharing reductions (CSRs) for many enrollees that limit out-of-pocket spending such as deductibles.
ASPE Issue Brief
Health Coverage Under the Affordable Care Act: Enrollment Trends and State Estimates
This Issue Brief presents current estimates of enrollment in health insurance coverage obtained through the ACA Marketplaces and the Medicaid expansion and the subsequent reductions in state-level uninsured rates since the ACA was implemented in 2014.Related Products